Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Savara, Inc. - Common Stock
(NQ:
SVRA
)
3.250
+0.020 (+0.62%)
Streaming Delayed Price
Updated: 11:15 AM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
242,685
Open
3.240
Bid (Size)
3.240 (14)
Ask (Size)
3.250 (34)
Prev. Close
3.230
Today's Range
3.125 - 3.320
52wk Range
2.815 - 5.700
Shares Outstanding
114,066,080
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
December 18, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Savara Inc.
Via
Business Wire
Performance
YTD
-25.63%
-25.63%
1 Month
-3.27%
-3.27%
3 Month
-29.50%
-29.50%
6 Month
-11.20%
-11.20%
1 Year
-32.01%
-32.01%
More News
Read More
Savara Announces New Employment Inducement Grant
November 22, 2024
From
Savara Inc.
Via
Business Wire
SVRA Stock Earnings: Savara Misses EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
November 22, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces Participation in Upcoming Healthcare Conferences
November 13, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 04, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
October 22, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
October 18, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
October 01, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
September 27, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
September 27, 2024
From
Savara Inc.
Via
Business Wire
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
September 24, 2024
From
Savara Inc.
Via
Business Wire
Savara to Host Analyst and Investor Webinar on September 30, 2024
September 23, 2024
From
Savara Inc.
Via
Business Wire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
September 08, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
September 06, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces New Employment Inducement Grant
August 16, 2024
From
Savara Inc.
Via
Business Wire
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
August 15, 2024
From
Savara Inc.
Via
Business Wire
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Savara Inc.
Via
Business Wire
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
June 28, 2024
From
Savara Inc.
Via
Business Wire
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
June 26, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 26, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.